Primary care respiratory treatment in the world's most populous nation reveals troubling gaps that could affect millions managing chronic lung disease. When standardized international guidelines exist for optimizing breathing medications, widespread deviations from these protocols suggest patients may not receive treatments best suited to their specific disease severity and symptom patterns.
Clinicians examined 646 Chinese COPD patients across Beijing and Chengdu primary care facilities, categorizing participants by symptom severity using established GOLD classification groups. One-third received no inhaled medications whatsoever, while those who did receive treatment often got regimens misaligned with their clinical profiles. The most prescribed combination was LABA/ICS bronchodilators with corticosteroids, used in nearly 30% of cases, followed by triple therapy adding LAMA medications in 26% of patients. Group B patients—those with moderate symptoms—showed particularly poor guideline adherence at just 4.2%.
This prescribing disconnect matters because inhaled medication selection should match individual symptom burden and exacerbation risk. Patients receiving inappropriate regimens may experience suboptimal symptom control, unnecessary side effects from overprescribed corticosteroids, or inadequate protection against breathing crises. The findings reflect broader challenges in respiratory care standardization across developing healthcare systems, where access to specialized pulmonary expertise remains limited. While this represents just one region's experience, the scale suggests systematic issues that could benefit from enhanced prescriber education and decision-support tools. The research highlights how evidence-based treatment protocols often struggle to translate from international guidelines into real-world primary care practice.